← Back to Screener
PROCEPT BioRobotics Corporation Common Stock (PRCT)
Price$25.73
Favorite Metrics
Price vs S&P 500 (26W)-32.38%
Price vs S&P 500 (4W)-12.01%
Market Capitalization$1.42B
All Metrics
Book Value / Share (Quarterly)$6.50
P/TBV (Annual)4.81x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)60.14%
Cash Flow / Share (Quarterly)$-1.04
Price vs S&P 500 (YTD)-24.23%
Gross Margin (TTM)63.70%
Net Profit Margin (TTM)-31.02%
EPS (TTM)$-1.72
10-Day Avg Trading Volume1.30M
EPS Excl Extra (TTM)$-1.72
Revenue Growth (5Y)109.03%
EPS (Annual)$-1.72
ROI (Annual)-22.89%
Gross Margin (Annual)63.70%
Net Profit Margin (5Y Avg)-87.86%
Cash / Share (Quarterly)$5.09
Revenue Growth QoQ (YoY)11.94%
ROA (Last FY)-18.81%
Revenue Growth TTM (YoY)37.22%
EBITD / Share (TTM)$-1.75
ROE (5Y Avg)-30.64%
Operating Margin (TTM)-33.71%
Cash Flow / Share (Annual)$-1.04
P/B Ratio3.87x
P/B Ratio (Quarterly)4.80x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.84x
Net Interest Coverage (TTM)-26.49x
ROA (TTM)-18.63%
EPS Incl Extra (Annual)$-1.72
Current Ratio (Annual)6.85x
Quick Ratio (Quarterly)5.62x
3-Month Avg Trading Volume1.50M
52-Week Price Return-52.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.48
P/S Ratio (Annual)4.60x
Asset Turnover (Annual)0.61x
52-Week High$66.85
Operating Margin (5Y Avg)-85.20%
EPS Excl Extra (Annual)$-1.72
CapEx CAGR (5Y)109.83%
26-Week Price Return-23.63%
Quick Ratio (Annual)5.62x
13-Week Price Return-19.86%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)6.85x
Enterprise Value$1,182.762
Revenue / Share Growth (5Y)97.92%
Asset Turnover (TTM)0.60x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.76x
Pretax Margin (Annual)-30.96%
Cash / Share (Annual)$5.09
3-Month Return Std Dev68.95%
Gross Margin (5Y Avg)54.49%
Net Income / Employee (TTM)$-0
ROE (Last FY)-26.12%
Net Interest Coverage (Annual)-35.41x
EPS Basic Excl Extra (Annual)$-1.72
Receivables Turnover (TTM)3.69x
Total Debt / Equity (Quarterly)0.14x
EPS Incl Extra (TTM)$-1.72
Receivables Turnover (Annual)3.69x
ROI (TTM)-22.13%
P/S Ratio (TTM)4.60x
Pretax Margin (5Y Avg)-87.85%
Revenue / Share (Annual)$5.55
Tangible BV / Share (Annual)$6.48
Price vs S&P 500 (52W)-87.49%
Year-to-Date Return-20.09%
5-Day Price Return7.16%
EPS Normalized (Annual)$-1.72
ROA (5Y Avg)-21.61%
Net Profit Margin (Annual)-31.02%
Month-to-Date Return0.52%
Cash Flow / Share (TTM)$-2.26
EBITD / Share (Annual)$-1.75
Operating Margin (Annual)-33.71%
LT Debt / Equity (Annual)0.14x
ROI (5Y Avg)-25.78%
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-1.72
P/TBV (Quarterly)4.81x
P/B Ratio (Annual)4.80x
Inventory Turnover (TTM)1.76x
Pretax Margin (TTM)-30.96%
Book Value / Share (Annual)$6.50
Price vs S&P 500 (13W)-22.72%
Beta0.91x
Revenue / Share (TTM)$5.49
ROE (TTM)-25.13%
52-Week Low$19.35
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
3.95
3.90
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PRCTPROCEPT BioRobotics Corporation Common Stock | 4.60x | 109.03% | 63.70% | -33.71% | $25.73 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
PROCEPT BioRobotics develops, manufactures, and sells image-guided robotic surgical systems for minimally invasive urologic procedures. The company's AquaBeam and HYDROS platforms primarily address the benign prostatic hyperplasia market, with revenue concentrated in the United States and expanding international operations.